Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
The Pacira Pharmaceuticals price is unchanged compared to yesterday.
Currently there is a rather positive sentiment for Pacira Pharmaceuticals with 5 Buy predictions and 0 Sell predictions.
With a target price of 30 € there is a positive potential of 31.58% for Pacira Pharmaceuticals compared to the current price of 22.8 €.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.000% | 0.885% | 4.587% | 21.925% | 5.556% | -29.630% | -53.659% |
| Collegium Pharmaceutical Inc | 0.000% | -1.290% | -2.548% | 19.531% | -26.087% | 50.000% | 48.544% |
| Supernus Pharmaceuticals | 0.000% | -4.455% | -6.763% | 26.974% | -10.233% | 40.876% | 75.455% |
| Savara Inc. | -0.430% | -2.344% | -11.259% | 110.180% | -11.962% | 44.907% | 336.075% |
Comments
Pacira BioSciences (PCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (PCRX) had its price target raised by Needham & Company LLC from $30.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat